Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
DRAFT Patient Data REGIONAL Acute Ischemic Stroke/TIA Orders Bar Code Area Bar Code Area Rev: 30JA12 Page: 1 of 4 DRUG & FOOD ALLERGIES Bullets are active orders*. Cross out orders not indicated (initial), place (9) in boxes as appropriate. POST t-PA TREATMENT FOR Date: ____________________ Time:ISCHEMIC _________ hSTROKE – FIRST 24 HOURS Admit to: Medicine Telemetry MRP:________________________________ Diagnosis: Thromboembolic Stroke ICU/CCU Other ______________ Neurologist Consultant: ___________________________________ High Risk TIA Date: ________________________ NIH Stroke Scale: Baseline score = ________ (See back pg 1) 24 H score (if applicable) = ________ Date: ________________________ No Yes If yes, when: Did patient receive ALTEPLASE (rt-PA)? (patient must be 24 hours post-thrombolytic to use these orders) Time: _________ Time: _________ Date: ___________________ Time: ______ MEDICATIONS: • Acetaminophen 650 mg PO/rectally q4h PRN if temperature greater than 37.5°C or if pain. Maximum 4000 mg per day (maximum 3000 mg per day if eGFR is less than 30 mL/min or frail elderly). Antiplatelet Therapy: STAT ASA 320 mg (4 x 80 mg) PO x 1 dose (if not already done as per Regional Stroke/TIA Initial Assessment) • Ongoing chewable ASA 80 mg PO/NG once daily • If NPO and no NG tube then 650 mg rectally once daily. Once NG in place, switch to ASA 80 mg via tube once daily. When able to swallow whole pill, switch to E.C. ASA 81 mg PO once daily (notify pharmacy). Clopidogrel 75 mg PO daily or ____________________ 300 mg loading dose Reassess dual therapy (ASA + Clopidogrel) at 30 days Aggrenox (ASA 25 mg/Dipyridamole 200 mg SR ) one capsule PO bid (complete non-formulary form; Physician to complete Pharmacare coverage form) • If Aggrenox prescribed, discontinue plain ASA above Venous Thromboembolism (VTE) Prophylaxis (see back of page 2 for more details): Dalteparin 5000 units subcutaneously once daily Heparin 5000 units subcutaneously q8h q12h Enoxaparin 40 mg subcutaneously once daily or 40 mg q12h if morbidly obese (BMI greater than 40) • Discontinue when mobilizing independently daily Therapeutic Anticoagulation (see back of page 2 for more details): • Continue with venous thromboembolism prophylaxis if previously ordered and start: Warfarin 5 mg PO x 1 day: ___________ (mm/dd, usually started day 2-14 of ischemic stroke, after asymptomatic ICH has been ruled out; or started immediately for patients with TIA and atrial fibrillation) INR daily, starting: ___________ (mm/dd) Discontinue venous thromboembolism prophylaxis when INR greater than 2 for 2 consecutive days Discontinue ASA when INR greater than 2 for 2 consecutive days Pharmacist anticoagulation dosing service (where applicable at sites) Other:________________________________________________ Physician Signature: _________________________ Physician Printed Name: ____________________________ DRAFT Patient Name Regional Acute Ischemic Stroke/TIA Orders (cont’d): NIH Stroke Scale Rev 30JA12 Patient Unit Number Back of Page 1 Recommended Frequency of Assessment : Initial & 24 hours and at Discharge National Institute of Health Stroke Scale (NIHSS) CATEGORY 1a. Level of Consciousness **Patients who score 2 or 3 on this item should be assessed using the Glasgow Coma Scale 1b. LOC questions: (month, age) 1c. LOC commands: (opens/closes eyes, make fist, release fist). May use gestures 2. Best Gaze: Patient follows examiner’s finger or face through full horizontal field 3. Visual: (introduce visual stimulus/threat to patients field quadrants) 4. Facial Palsy (show teeth, raise eyebrows, squeeze eyes shut). May use gestures 5a. Motor arm – Left Test each limb independently for 10 seconds. Sitting: Arms outstretched 90° Supine: Arms at 45° Encourage best effort. 5b.Motor arm – Right (as above) 6a. Motor Leg – Right Test each limb independently: with patient supine, elevate extremity to 30°and score drift/movement over 5 sec. 6b. Motor Leg – Left (as above) 7. Limb ataxia (finger – nose, heel down shin) 8. Sensory (pin prick to face, arm, trunk, and leg – compare side to side. Aphasic pt: assess grimace 9. Best language (name item, describe a picture, and read sentences) 10. Dysarthria (Evaluate speech clarity by having patient read or repeat listed words) 11.Extinction and inattention (use information from prior testing to identify neglect or double simultaneous stimuli testing) Date and time CHOOSE THE BEST RESPONSE Alert, and keenly responsive Not alert - obey, answer, or respond to minor stimulation Not alert - responds to repeated or painful stimuli Unresponsive or responds only to motor, autonomic reflex Answers both correctly Answers one correctly Answers neither question correctly Answers both correctly Answers one correctly Answers neither question correctly Normal Partial gaze palsy; abnormal gaze in one or both eyes Forced deviation –deviation or total paresis not overcomed by oculocephalic maneuver (Doll’s eyes) No visual loss Partial hemianopia -or quadrant field deficit Complete hemianopia - dense field loss, (such as ½) Bilateral hemianopia (blind) Normal Minor paralysis - mild asymmetry on smiling Partial paralysis - paralysis of lower face Complete - one or both sides paralysis of upper, lower face 0 1 2 3 0 1 2 0 1 2 0 1 2 No drift (limb holds for 10 seconds) Drift (limb drifts downward; does not fall/ rests on support) Some effort against gravity (drift to fall on a support) No effort against gravity - trace movement, limb falls No voluntary movement Amputation, joint fusion, etc. 0 1 2 3 4 X No drift (limb holds for full 5 seconds) Drift (limb drifts downward; does not fall to rest on support) Some effort against gravity (drift to fall on a support) No effort against gravity -trace movement, limb falls No voluntary movement Amputation, joint fusion, etc. Absent Present in one limb Present in two limbs Normal Mild to moderate sensory loss (less sharp/dullness) Sensory or total sensory loss (not aware of touch) No aphasia Mild to moderate aphasia(reduced fluency/comprehension) Sever aphasia (communication exchange very limited) Mute, global aphasia Normal articulation Mild to moderate dysarthria (slurred but understandable) Severe dysarthria (unintelligible or worse) Intubated/trached (or other physical barrier) No abnormality (no neglect) Visual, tactile, auditory, spatial, or personal inattention, or extinction to bilateral stimulation in one sensory modulation Profound: more than one modality affected 0 1 2 3 4 X 0 1 2 0 1 2 0 1 2 3 0 1 2 3 0 1 Total Score 0 1 2 3 0 1 2 3 2 R L R L R L R L R L R L DRAFT Patient Data REGIONAL Acute Ischemic Stroke/TIA Orders Bar Code Area Bar Code Area Rev: 30JA12 Page: 2 of 4 DRUG & FOOD ALLERGIES Bullets are active orders*. Cross out orders not indicated (initial), place (9) in boxes as appropriate. Date: ___________________ Time: __________ POST t-PA TREATMENT FOR ISCHEMIC STROKE – FIRST 24 HOURS MEDICATIONS (continued) ACE Inhibitor: _____ mg _____ time(s) daily • Ramipril • Perindopril _____ mg _____ time(s) daily • Other _______________________________ Lipid Lowering Medication: • Simvastatin 10 mg 20 mg 40 mg PO once daily (at 1700 h) • Atorvastatin 40 mg 80 mg PO once daily Antihypertensive Medication: • Target BP Range = ______________ ; Physician to calculate ~ 15% BP reduction in first 24h after stroke onset (maximum 25% BP reduction; see back of page 2 for calculation table) • Notify physician if BP remains outside target range or neurological deterioration occurs Blood Pressure (mmHg) Systolic BP less than 220 and Diastolic BP less than 120 Intervention • • • Observe unless other end-organ involvement, e.g. aortic dissection, acute myocardial infarction, pulmonary edema, hypertensive encephalopathy Treat other symptoms of stroke such as headache, pain, agitation, nausea, and vomiting. Treat other acute complication of stroke (including hypoxia, increased intracranial pressure) Critical Care Areas: Systolic BP greater than 220 mmHg or Diastolic BP greater than 120 mmHg • Labetalol 10 mg IV over 1- 2 min. May repeat Labetalol 10-80 mg (double previous dose) IV q10 min PRN to a maximum of 300 mg in 24 h. Contact physician if target BP not achieved after 3 doses. HOLD Labetalol if heart rate less than 60 BPM. Monitor BP q10 min until target BP achieved for 2 consecutive readings; then vital signs and neurovital signs q30 min x 2, then q2h x 24 h. (Note: Labetalol onset 5 minutes, peak 15 minutes, duration 2 to 4 h) • If BP rises above target, restart BP protocol as above. Acute Care Areas: • Captopril 6.25 to 12.5 mg sublingually STAT, then q30 MIN PRN if sBP greater than 220 mmHg or dBP greater than 120 mmHg on two readings 20 minutes apart. Contact physician if target BP not achieved 1 h of cumulative dose 25 mg given. After each dose check BP at 15 min, 30 min, 1 h and q2h for 8 h and then until stable. (Note: Captopril onset 15 minutes, peak 1 h, duration 6 to 8 h.) hydrALAZINE 10 to 20 mg IV in 50 mL NS, infused over 1h PRN (maximum of 300 mg in 24 h; monitor blood pressure q15 min during infusion and at 15 and 30 minutes after each dose; contact physician if blood pressure not controlled after 3 doses and consider need for higher level of care Other (see suggestions on back of page 2)___________________________ Physician Signature: ___________________________ Physician Printed Name: _____________________________ DRAFT REGIONAL Acute Ischemic Stroke/TIA Orders (cont’d): Patient Name Blood Pressure & Anticoagulation Guidelines Patient Unit Number Back of Page 2 Rev: 30JA12 BP Reduction Chart: 15% & 25% Systolic BP 220 230 240 250 260 270 280 290 300 310 320 Diastolic BP 220 210 200 190 180 170 160 150 140 130 120 15% Reduction 187 196 204 213 221 230 238 247 255 264 272 25% Reduction 165 173 180 188 195 203 210 218 225 233 240 15% Reduction 187 179 170 162 153 145 136 128 119 111 102 25% Reduction 165 158 150 143 135 128 120 113 105 98 90 Other Antihypertensive Options Caution: ACEI used in patients receiving Alteplase (rt-PA) have been associated with slightly increased risk of angioedema • Enalaprilat – 0.625 – 1.25mg IV q6h prn; incremental doses of 0.625-1.25 mg may be repeated every 15-60 minutes to a maximum of 5 mg in 6 h • Lisinopril 5-15 mg SL daily • Nitroglycerine patch (40-60 minute onset) • Hydralazine 10-25 mg QID PO • Amlodipine 2.5-5 mg daily PO VTE Prophylaxis VTE Prophylaxis should be offered if the patient: • Has had or is expected to have significantly reduced mobility for 3 or more days, OR • Is expected to have ongoing reduced mobility relative to their normal state, and has 1 or more of the following risk factors: o active cancer or cancer treatment o age over 60 y o critical care admission o dehydration o known thrombophilias o obesity (BMI over 30 kg/m2) o any significant comorbidity (e.g heart disease; metabolic endocrine or respiratory pathology; acute infectious disease; inflammatory conditions) o personal history or first-degree relative with a history of VTE o use of hormone replacement therapy or estrogen-containing contraceptive o varicose veins with phlebitis (Venous thromboembolism: reducing the risk, NICE Clinical Guideline 92, January 2010) VTE prophylaxis should continue for the duration of increased risk • in long term immobile patients, the risk of VTE is significantly reduced after 4 months of immobility. Therapeutic Anticoagulation • Treatment dose heparin/heparinoid anticoagulation is not recommended in acute ischemic stroke and atrial fibrillation • Optimal timing of oral anticoagulation following acute ischemic stroke (with atrial fibrillation) is unclear; usually started day 2-14 of ischemic stroke, after asymptomatic ICH has been ruled out; or started immediately for patients with TIA and atrial fibrillation) • Dabigatran and Rivaroxaban are non-formulary. Re-ly and Rocket-AF trials did not enroll patients within first 14 days of stroke, nor first 3-6 months of severe stroke DRAFT Patient Data REGIONAL Acute Ischemic Stroke/TIA Orders Bar Code Area Bar Code Area Page: 3 of 4 Rev: 30JA12 DRUG & FOOD ALLERGIES Bullets are active orders*. Cross out orders not indicated (initial), place (9) in boxes as appropriate. POST_________________ t-PA TREATMENT FOR ISCHEMIC STROKE – Date: Time:_________ FIRST 24 HOURS MEDICATIONS (continued): Blood Glucose Management: • Glucometer qid (ac tid + hs). If on enteral feeds, glucometer Q6H INSULIN Regimen as at home (Specify): _______________________________________________ _________________________________________________________________________________ INSULIN Basal: NPH ________________________________ (dose and times) Other ________________________________ INSULIN REGULAR HUMAN subcutaneously (per dosing specified below) tid ac at 0730h, 1130h, 1630h (NOT qhs unless specified below) Serum Glucose (mmol/L) Less than 4 4-10 10.1-12 12.1-14 14.1-16 16.1-18 18.1-20 Greater than 20 □ Standard Regimen □ Resistant Regimen □ Other Regimen No insulin; initiate Hypoglycemia Protocol; notify MD 0 0 2 units 5 units 4 units 8 units 6 units 10 units 8 units 12 units 10 units 14 units 12 units & call MD 16 units & call MD □ HS Insulin units units units units units units __units & call MD Standard Regimen: suggested starting point for most patients (thin, elderly, or on steroids, insulin and oral hypoglycaemic medications) Resistant Regimen: suggested starting point for overweight/previously high insulin requirement patients DIET: • • • Screen for swallowing impairment using Regional Stroke Swallowing Screening Tool NPO until swallow screening completed If swallowing is impaired, order a swallowing assessment and keep patient NPO. If swallowing is normal, initiate diet as appropriate: □ NPO □ DAT □ Diabetic _______ kcal □ Dysphagia ________________ □ Other _________________ • Call Physician if: patient becomes NPO or when enteral feeding is initiated or stopped; persistent nausea and vomiting unresponsive to treatment, a change in level of consciousness. Physician Signature: ___________________________ Physician Printed Name: _____________________________ DRAFT REGIONAL Acute Ischemic Stroke/TIA Orders Bar Code Area Patient Data Bar Code Area Rev: 30JA12 Page: 4 of 4 DRUG & FOOD ALLERGIES Bullets are active orders*. Cross out orders not indicated (initial), place (9) in boxes as appropriate. Date: _________________ Time:_________ POST t-PA TREATMENT FOR ISCHEMIC STROKE – FIRST 24 HOURS INVESTIGATIONS (only if not already completed): • • • • • Urinalysis Troponin I Hemoglobin A1c (glycosylated hemoglobin) Chest X-ray: □ portable □ PA Other _____________________ CT Head non-contrast CT Angio Other __________________ ECG (12 lead) CBC, electrolytes, BUN, SCr, random blood glucose, INR, PTT, TSH, CK Fasting blood glucose (minimum 12 hour fasting period) Fasting lipid profile (minimum 12 hour fasting period) Carotid Doppler ultrasound Echocardiogram Holter Monitor MONITORING: • • • • • Vital signs, SpO2 and Neurovital signs [Glasgow coma scale, pupil and motor strength assessments] q2h or q ___h for first 24h, then q4h x 24h, then q8h x 24h. Notify Physician if Glasgow Coma Scale changes by more than 1 POINT or signs of neurological deterioration. Titrate 02 to keep Sp02 saturations greater than or equal to 92% or ____ % Braden Scale on admission then daily x4days then reassess; discontinue when patient ambulating Glucometer qid (ac tid + hs). If on enteral feeds, glucometer Q6H Cardiac Monitor (Telemetry) x 24 hours then reassess ACTIVITY: AAT Head of Bed Up (not to exceed 30 degrees): ____ Bedrest Other ___________ REFERRALS: • • • • • Physiotherapist Occupational Therapist Speech Language Pathologist Dietitian Transition Planning Patient/Family Counselling Psychosocial Assessment Social Worker: Pharmacist: Medication history/review Education Other _____________________ Physician Signature: _________________________ Physician Printed Name: ________________________